Literature DB >> 22882974

Cell-surface metalloprotease ADAM12 is internalized by a clathrin- and Grb2-dependent mechanism.

Dorte Stautz1, Anthony Leyme, Michael Vibo Grandal, Reidar Albrechtsen, Bo van Deurs, Ulla Wewer, Marie Kveiborg.   

Abstract

ADAM12 (A Disintegrin And Metalloprotease 12), a member of the ADAMs family of transmembrane proteins, is involved in ectodomain shedding, cell-adhesion and signaling, with important implications in cancer. Therefore, mechanisms that regulate the levels and activity of ADAM12 at the cell-surface are possibly crucial in these contexts. We here investigated internalization and subsequent recycling or degradation of ADAM12 as a potentially important regulatory mechanism. Our results show that ADAM12 is constitutively internalized primarily via the clathrin-dependent pathway and is subsequently detected in both early and recycling endosomes. The protease activity of ADAM12 does not influence this internalization mechanism. Analysis of essential elements for internalization established that proline-rich regions in the cytoplasmic domain of ADAM12, previously shown to interact with Src-homology 3 domains, were necessary for proper internalization. These sites in the ADAM12 cytoplasmic domain interacted with the adaptor protein growth factor receptor-bound protein 2 (Grb2) and knockdown of Grb2 markedly reduced ADAM12 internalization. These studies establish that internalization is indeed a mechanism that regulates ADAM cell surface levels and show that ADAM12 internalization involves the clathrin-dependent pathway and Grb2.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22882974     DOI: 10.1111/j.1600-0854.2012.01405.x

Source DB:  PubMed          Journal:  Traffic        ISSN: 1398-9219            Impact factor:   6.215


  10 in total

1.  Sorting nexin 9 (SNX9) regulates levels of the transmembrane ADAM9 at the cell surface.

Authors:  Kasper J Mygind; Theresa Störiko; Marie L Freiberg; Jacob Samsøe-Petersen; Jeanette Schwarz; Olav M Andersen; Marie Kveiborg
Journal:  J Biol Chem       Date:  2018-04-05       Impact factor: 5.157

2.  Modulation of type II TGF-β receptor degradation by integrin-linked kinase.

Authors:  Linda Vi; Stellar Boo; Samar Sayedyahossein; Randeep K Singh; Sarah McLean; Gianni M Di Guglielmo; Lina Dagnino
Journal:  J Invest Dermatol       Date:  2014-09-30       Impact factor: 8.551

3.  An unexpected role for the conserved ADAM-family metalloprotease ADM-2 in Caenorhabditis elegans molting.

Authors:  Braveen B Joseph; Phillip T Edeen; Sarina Meadows; Shaonil Binti; David S Fay
Journal:  PLoS Genet       Date:  2022-05-31       Impact factor: 6.020

Review 4.  A disintegrin and metalloproteinase-12 (ADAM12): function, roles in disease progression, and clinical implications.

Authors:  Erin K Nyren-Erickson; Justin M Jones; D K Srivastava; Sanku Mallik
Journal:  Biochim Biophys Acta       Date:  2013-05-13

5.  Alternative mRNA splicing generates two distinct ADAM12 prodomain variants.

Authors:  Sara Duhachek-Muggy; Hui Li; Yue Qi; Anna Zolkiewska
Journal:  PLoS One       Date:  2013-10-07       Impact factor: 3.240

6.  ADAM8 as a drug target in pancreatic cancer.

Authors:  Uwe Schlomann; Garrit Koller; Catharina Conrad; Taheera Ferdous; Panagiota Golfi; Adolfo Molejon Garcia; Sabrina Höfling; Maddy Parsons; Patricia Costa; Robin Soper; Maud Bossard; Thorsten Hagemann; Rozita Roshani; Norbert Sewald; Randal R Ketchem; Marcia L Moss; Fred H Rasmussen; Miles A Miller; Douglas A Lauffenburger; David A Tuveson; Christopher Nimsky; Jörg W Bartsch
Journal:  Nat Commun       Date:  2015-01-28       Impact factor: 14.919

7.  Prevention of excitotoxicity-induced processing of BDNF receptor TrkB-FL leads to stroke neuroprotection.

Authors:  Gonzalo S Tejeda; Gema M Esteban-Ortega; Esther San Antonio; Óscar G Vidaurre; Margarita Díaz-Guerra
Journal:  EMBO Mol Med       Date:  2019-06-03       Impact factor: 12.137

Review 8.  Regulation of Fibrotic Processes in the Liver by ADAM Proteases.

Authors:  Dirk Schmidt-Arras; Stefan Rose-John
Journal:  Cells       Date:  2019-10-09       Impact factor: 6.600

9.  Identification of SH3 domain proteins interacting with the cytoplasmic tail of the a disintegrin and metalloprotease 10 (ADAM10).

Authors:  Henriette Ebsen; Marcus Lettau; Dieter Kabelitz; Ottmar Janssen
Journal:  PLoS One       Date:  2014-07-18       Impact factor: 3.240

10.  CAMKV Is a Candidate Immunotherapeutic Target in MYCN Amplified Neuroblastoma.

Authors:  Robyn T Sussman; Jo Lynne Rokita; Kevin Huang; Pichai Raman; Komal S Rathi; Daniel Martinez; Kristopher R Bosse; Maria Lane; Lori S Hart; Tricia Bhatti; Bruce Pawel; John M Maris
Journal:  Front Oncol       Date:  2020-03-06       Impact factor: 6.244

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.